Citations

Clear

4510 citation(s) found for "Scott, C".

Diagnosing a child presenting with symptoms suggesting Sjögren’s disease: a tool for clinical practice
Stern, Sara M , Basiaga, Matthew L. , Cha, Seunghee , Thatayatikom, Akaluck , Treemarcki, Erin , Randell, Rachel L. , Dizon, Brian , Appenzeller, Simone , Edens, Cuoghi , Orrock, Janet , Tiger, Sharon, Diianni, Jamie, Amoafo, Linda , Lieberman, Scott M. , Treemarcki, Erin B , Dizon, Brian L P , Orrock, Janet E , Randell, Rachel L , Stern, Sara

Mayo Clinic

Rheumatology | December 2, 2024 | Volume: 64 | Issue: 5 | Pages: 3039-3047

10.1093/rheumatology/keae640 | PMID 39673525 Get It

Abstract Objective Childhood SjD (cSjD) is a rare disease. There are no widely accepted diagnostic or classification criteria for cSjD. To fill this gap, members from the CARRA Sjögren Disease Workgroup and the International Childhood Sjögren Disease Workgroup created a clinical diagnostic algorithm. This study evaluated the accuracy of this algorithm using an international cohort of participants with clinician-diagnosed cSjD. Methods First, experts developed a cSjD diagnostic algorithm through a series of virtual workgroup meetings. Using the adult classification criteria as a framework, experts modified the algorithm through opinion and literature review. The group discussed and finalized each algorithm step by achieving majority rule. Then, R statistical software was used to evaluate each participant’s disease status in the diagnostic algorithm via an international cohort of 300 cSjD cases. Results The diagnostic algorithm has three distinct clinical pathways representing the key clinical presentation in cSjD: parotitis, extraglandular manifestations, and sicca symptoms. The algorithm showed an overall sensitivity of 75% in the population that had enough data to complete at least one pathway of the algorithm (n = 100 filtered out of 300). The parotitis (70%) and sicca pathways (82%) had the highest sensitivity, and the extraglandular pathway (52%) had the lowest. Conclusion As cSjD lacks a diagnostic strategy, this algorithm provides a clinical tool for evaluating children with cSjD-like symptoms. It performed well in an international cohort of cSjD, supporting the integration of this algorithm into clinical practice; however, its utility may be limited by low utilization of diagnostic testing in this population.
Robotic carotid artery stenting: a multicenter, propensity score–matched analysis of clinical outcomes and cost-effectiveness
Patel, Shray , Scott, Kyle, Abbas, Rawad , Fuleihan, Antony A. , Sivaganesan, Ahilan, Tjoumakaris, Stavropoula I., Rosenwasser, Robert H. , Srinivasan, Visish M. , Burkhardt, Jan‐Karl , Burkhardt, Jan‐Karl , Roy, Joanna M. , Musmar, Basel , Sarikonda, Advith , Scott, Kyle, Tjoumakaris, Stavropoula , Gooch, Michael Reid , Jabbour, Pascal

Mayo Clinic

Neurosurgical Focus | December 1, 2024 | Volume: 57 | Issue: 6 | Pages: E10

10.3171/2024.9.focus24479 | PMID 39616641 Get It

OBJECTIVE Preclinical studies suggest that robotic carotid artery stenting (CAS) could be superior to manual CAS. However, very limited comparative data exist for patients who have undergone robotic versus manual CAS. In addition, no data exist comparing the costs of manual and robotic CAS. METHODS All robotic CAS cases at two academic neurosurgery centers were retrospectively reviewed and 1:1 propensity matched with manual CAS cases. Personnel costs, supply costs, and total procedure costs were collected in collaboration with hospital administration by using time-driven activity-based cost analysis. RESULTS A total of 24 robotic CAS operations were performed between 2019 and 2023. Comorbidities and baseline procedural characteristics were well matched between robotic and manual cases. Unplanned manual conversion was observed in only 1 robotic case (4.2%). Robotic CAS complications and outcomes were comparable to manual. Robotic CAS was associated with a significantly increased fluoroscopy time (29.0 vs 19.2 minutes; p < 0.001). Robotic procedure time (88.9 ± 18.2 minutes) was significantly (p = 0.003) longer than manual time (68.72 ± 22.4 minutes). Health personnel costs ($1589.71 ± $176.92 vs $1375.99 ± $233.39, p = 0.005); supply costs ($3918.25 ± $421.20 vs $2152.74 ± $1030.26, p < 0.001); and total procedure costs ($5306.11 ± $608.95 vs $3437.56 ± $1165.67, p < 0.001) were greater for robotic CAS. CONCLUSIONS In the first multicenter study and largest sample to date, the authors show that robotic CAS, with a low rate of procedural failure and postoperative complications, is safe and feasible. In addition, robotic CAS achieves comparable clinical outcomes to manual CAS. Robotic CAS was associated with increased fluoroscopy time, but fluoroscopy time decreased as operators gained familiarity with the CorPath GRX system. Robotic CAS was associated with a greater procedural cost, which was driven by greater personnel and supply costs. Robotic CAS failed to show superiority to manual CAS. These findings set a foundation for randomized controlled trials of robotic CAS, and also highlight the need for further studies to optimize robotic CAS and reduce its associated costs.
Implementing evidence‐based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024
Bryce, Alan H. , Beltran, Himisha , Hussain, Maha , Armstrong, Andrew J. , Calais, Jérémie , Dorff, Tanya B. , Gomella, Leonard G. , Higano, Celestia, Morris, David S. , Petrylak, Daniel P. , Reiter, Robert E. , Ryan, Charles J. , Sellinger, Scott B., Srinivas, Sandy, Taplin, Mary‐Ellen , Zhang, Tian , McKay, Rana R. , Koo, Phillip J. , Crawford, E. David , Armstrong, Andrew J , Dorff, Tanya , Morris, Michael J , Spratt, Daniel E , Tagawa, Scott T , Zhang, Tian , Bryce, Alan H , Hussain, Maha H A , Calais, Jeremie , Agarwal, Neeraj, Sartor, Oliver , Shore, Neal D. , Antonarakis, Emmanuel S. , Carducci, Michael A. , Efstathiou, Jason A. , Gleave, Martin , Higano, Celestia S. , Hope, Thomas A. , Iagaru, Andrei H. , Morgans, Alicia K. , Morris, David S., Morris, Michael J. , Rettig, Matthew B. , Spratt, Daniel E. , Tagawa, Scott T. , Yu, Evan Y.

Mayo Clinic

Cancer | December 1, 2024 | Volume: 131 | Issue: 1 | Pages: No page available

10.1002/cncr.35612 | PMID 39616467 Get It

AbstractCurrent US clinical practice guidelines for advanced prostate cancer management contain recommendations based on high‐level evidence from randomized controlled trials; however, these guidelines do not address the nuanced clinical questions that are unanswered by prospective trials but nonetheless encountered in day‐to‐day practice. To address these practical questions, the 2024 US Prostate Cancer Conference (USPCC 2024) was created to generate US‐focused expert clinical decision‐making guidance for circumstances in which level 1 evidence is lacking. At the second annual USPCC meeting (USPCC 2024), a multidisciplinary panel of experts convened to discuss ongoing clinical challenges related to 5 topic areas: biochemical recurrence; metastatic, castration‐sensitive prostate cancer; poly [ADP‐ribose] polymerase inhibitors; prostate‐specific membrane antigen radioligand therapy; and metastatic, castration‐resistant prostate cancer. Through a modified Delphi process, 34 consensus recommendations were developed and are intended to provide clinicians who manage prostate cancer with guidance related to the implementation of novel treatments and technologies. In this report, the authors review the areas of consensus identified by the USPCC 2024 experts and evaluate ongoing unmet needs regarding translational application of the current clinical evidence.
Lipoprotein (a): Underrecognized Risk with a Promising Future
Manzato, Matteo, Wright, R. Scott , Jaffe, Allan S. , Vasile, Vlad C. , Manzato, Matteo , Manzato, Matteo , Jaffe, Allan S.

Mayo Clinic

Reviews in Cardiovascular Medicine | November 27, 2024 | Volume: 25 | Issue: 11 | Pages: No page available

10.31083/j.rcm2511393 | PMID 39618878 Get It

Lipoprotein a (Lp(a)) is a lipid biomarker that binds cholesterol and bears independent cardiovascular risk. Strategies to lower the level of Lp(a) and mitigate such risk are important both for primary and secondary prevention. Currently there are no approved therapies targeting Lp(a) directly. Lipid lowering therapies prescribed routinely may have no effect on Lp(a) levels. Some agents such as niacin and estrogens can significantly decrease Lp(a), but their use is not recommended due to their adverse safety profile. Statins increase Lp(a) levels by 10–20%, questioning the benefit of such therapy when this biomarker is elevated. The Food and Drug Administration (FDA) endorses new agents to address dyslipidemia such as proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9-i) and Inclisiran, a small interfering RNA. These approaches have been shown to also significantly reduce Lp(a), but more clinical data is needed before implementing their use in clinical practice. Clinical trials are currently ongoing to test the efficacy of newly developed antisense oligonucleotides and small interfering RNAs targeting the gene encoding for Lp(a) in hepatocytes, while other investigations assess small molecules that inhibit Lp(a) assembly. This review summarizes the pathophysiology and clinical implications of Lp(a) elevation, and focuses on proposed Lp(a) therapies and the current state of the clinical trials of such novel agents.
Sex Differences in Patient-Reported Outcomes and Perception of Ascites Burden Among Outpatients With Decompensated Cirrhosis and Ascites
Wong, Florence , Reddy, K. Rajender , Tandon, Puneeta , Lai, Jennifer C. , García‐Tsao, Guadalupe , O'leary, Jacqueline, Biggins, Scott W. , Vargas, Hugo E. , Thacker, Leroy R. , Kamath, Patrick S. , Bajaj, Jasmohan S. , Group, The NACSELD III Study, O'Leary, Jacqueline G , Thacker, Leroy R , Tandon, Puneeta , Wong, Florence , Lai, Jennifer , Vargas, Hugo E , García–Tsao, Guadalupe , Group, The NACSELD III Study

Mayo Clinic

American Journal of Gastroenterology | November 27, 2024 | Volume: 120 | Issue: 8 | Pages: 1791-1799

10.14309/ajg.0000000000003251 | PMID 39601412 Get It

INTRODUCTION: Perception of the ascites burden and its effects on quality of life may be different between sexes. This study assessed sex differences in perception of ascites burden and its impact on health-related quality of life (HRQoL) in patients with recurrent or refractory ascites. METHODS: The North American Consortium for the Study of End-stage Liver Disease prospectively enrolled outpatients with cirrhosis and large ascites requiring repeat large volume paracenteses. Demographics, laboratory results, comorbidities, medications, frailty measurements, and self-reported questionnaires related to functional status, physical activities, and HRQoL (generic = Short Form 36 and ascites specific = Ascites Questionnaire) were compared between sexes. RESULTS: In total, 392 men (59.6 ± 10.7 years) and 184 women (59.5 ± 11.1 years) with predominantly alcohol-related liver disease (51% and 43%, respectively) and median Model for End-Stage Liver Disease-Na: 13 were enrolled. Both groups had similar comorbidities and cirrhosis complications, ascites duration and severity, and frailty scores ( P = 0.94). Women had more symptoms related to their ascites (Ascites Questionnaire score = 66 ± 21 vs 60 ± 21 in men, P = 0.001) (higher value = feeling worse). 35% of women felt depressed vs 22% of men ( P = 0.0009), with lower mental but not physical functioning components of Short Form 36 ( P = 0.019). Women continued to conduct their daily activities as adequately as men as indicated by Duke Status Activity Index ( P = 0.27) and Godin Leisure Activity Index ( P = 0.47). DISCUSSION: Women with cirrhosis and ascites experienced worse emotional HRQoL than men without difference in daily function. Our analyses underscore the differences in the lived experience of women vs men with cirrhosis and highlight the need for patient-reported metrics to provide patient-centered care.
Society of Radiologists in Ultrasound response to ‘Proposed simplified protocol for initial assessment of endometriosis with transvaginal ultrasound’
Young, Scott W. , VanBuren, W., Kho, Rosanne M. , Groszmann, Yvette S. , Feldman, Myra , Khan, Zaraq , Young, S. L., Endometriosis, the Society of Radiologists in Ultrasound Consensus Panel on Routine Pelvic Ultrasound for, Young, Scott W , Jha, Priyanka , Rodgers, Shuchi K. , Burnett, Tatnai L. , Chamié, Luciana Pardini , Horrow, Mindy M. , Young, S. L., Young, Steven L. , Endometriosis, the Society of Radiologists in Ultrasound Consensus Panel on Routine Pelvic Ultrasound for

Mayo Clinic

Ultrasound in Obstetrics & Gynecology | November 27, 2024 | Volume: 65 | Issue: 2 | Pages: 243-245

10.1002/uog.29147 | PMID 39601344 Get It

Linked article: This Correspondence comments on Deslandes and Leonardi. Click here to view the article.
Neurohospitalist Core Competencies
Wold, Jana , Robertson, Jetter , Jeevarajan, Jerome , Knox, Molly G., Thatikunta, Prateek , Solorzano, Guillermo E., Galetta, Kristin , Dujari, Shefali , Goyal, Tarini , Ehrlich, Matthew , Donnelly, J., Marriott, Elizabeth , Mandge, Vishal , Dhoot, Roshni , Luedke, Matthew W. , Maas, Matthew B., Yu, Mei , Tolédano, Michel B. , Palaganas, Jamie L., Kvam, Kathryn A. , Dugue, Rachelle , Meltzer, Ethan , Touma, Lahoud , Shah, Maulik , Douglas, Vanja C. , Orjuela, Karen , Klein, Joshua P. , Likosky, David, Simpson, Jennifer , Richie, Megan , Dohle, Carolin, Morris, Jane G. , Gold, Carl A. , Maas, Matthew B. , Wold, Jana J , Ehrlich, Matthew E , Mustafa, Rafid , Kvam, Kathryn , Meltzer, Ethan , Shah, Maulik P , Orjuela, Karen , Klein, Joshua P , Gold, Carl A , Yu, Margaret Y., Toledano, Michel, Mustafa, Rafid , Palaganas, Jamie, Scott, Brian J.

Mayo Clinic

The Neurohospitalist | November 26, 2024 | Volume: 15 | Issue: 1 | Pages: 13-84

10.1177/19418744241297187 | PMID 39610897 Get It

The Neurohospitalist Core Competencies comprise a set of competency-based learning objectives that encapsulate the knowledge, skills, and attitudes of neurohospitalitists who specialize in the care of hospitalized patients with neurologic conditions. These competencies serve to characterize the rapidly expanding field of neurohospitalist medicine. The 27 chapters are divided into 3 sections entitled: neurological conditions, clinical interventions and interpretation of ancillary studies, and neurohospitalist role in the healthcare system. Each individual learning objective in the chapters describes a specific concept with an action verb to illustrate the behavior that the neurohospitalist exhibits. The individual neurohospitalist may not exhibit mastery in each of the topics included as individual practices vary in scope and practice pattern. A few examples of how the complete set of competencies may be used include in the creation of curricula for neurohospitalist fellowships, to assist in defining the scope of practice of neurohospitalists for administrative leaders of hospitals and departments, and in influencing the direction of further research and quality improvement in the field.
Natriuretic peptide levels and predicting risk of developing new diabetes mellitus and metabolic syndrome
Singh, Jasraj , Scott, Christopher G., Chen, Horng H. , Adel, Fadi W , Adel, Fadi

Mayo Clinic

Diabetes, Obesity and Metabolism | November 25, 2024 | Volume: 27 | Issue: 2 | Pages: 777-784

10.1111/dom.16073 | PMID 39587371 Get It

Abstract Aims Define the relationship between N‐terminal atrial natriuretic peptide (NT‐ANP) levels and incident metabolic syndrome and type 2 diabetes mellitus (‘metabolic disease’) in healthy adults and develop a risk prediction score. Materials and Methods Retrospective cohort study of Olmsted County Heart Function Study participants, a random sampling of county residents aged 45 years and older ( n = 2042). Clinical data were collected during enrolment between 1997 and 2000 and upon follow‐up 4 years later. Outcomes were followed for 8 years. We studied 715 subjects without metabolic disease at enrolment who completed follow‐up, assessing incident metabolic disease as the primary outcome. Youden's index was used to identify optimal cut‐points and develop the risk score. Results Upon multivariate analysis adjusting for age gender, HDL and triglycerides, higher baseline serum NT‐ANP levels were associated with a lower risk of metabolic disease (OR: 0.65, CI 0.49–0.85, p = 0.002). Higher baseline serum insulin and aldosterone levels were associated with higher risk of incident metabolic disease (OR: 2.04, CI 1.57–2.65, p < 0.001; OR: 1.43, CI 1.14–1.81, p = 0.002, respectively). Baseline serum NT‐ANP < 3337 pg/mL was 96.6% sensitive for future development of metabolic disease. A weighted score including all three biomarkers was 78.6% sensitive and 77.3% specific. Conclusions In healthy adults aged 45 years or older, higher baseline NT‐ANP levels are associated with a lower four‐year risk of developing metabolic disease. Serum NT‐ANP levels are a sensitive biomarker of future risk of metabolic disease and have screening utility when combined with insulin and aldosterone levels into a composite score.
Moving beyond tokenism: Sustaining engagement of persons living with dementia in identifying emergency research priorities
Sandoval, Jacqueline , Carpenter, Christopher R. , Shah, Manish N. , Dussetschleger, Jeffrey, Gil, Heidi, Jaspal, Naveena, Jobe, Deborah, Vann, Allan, Webb, Teresa, Hwang, Ula , Carpenter, Christopher R , Shah, Manish N , Hwang, Ula , Gilmore‐Bykovskyi, Andrea L , Dresden, Scott M. , Ellenbogen, Michael I.

Mayo Clinic

Journal of the American Geriatrics Society | November 22, 2024 | Volume: 73 | Issue: 5 | Pages: 1344-1352

10.1111/jgs.19269 | PMID 39576051 Get It

Abstract Introduction The Geriatric Emergency Care Applied Research Network 2.0‐Advancing Dementia Care (GEAR 2.0‐ADC) aims to advance research efforts to improve the emergency care of persons living with dementia (PLWDs). Objective To support this objective, GEAR 2.0‐ADC convened a virtual consensus conference to prioritize emergency care research opportunities for PLWDs inclusive of perspectives of PLWDs to ensure identification of research gaps in response to their experiences and priorities. Inclusion of PLWDs as research partners is increasingly recognized as a best practice, however, approaches to facilitating consensus participation are lacking. Methods Best practices for supporting the engagement of PLWDs in a consensus conference, applied across its three phases (pre‐conference, during the conference, and post‐conference), include: establishing a learning environment focused on research priorities before the event, presenting information in ways that align with participants' learning preferences while accommodating cognitive impairments, and providing multiple opportunities and methods for gathering post‐conference feedback from PLWDs. Results These strategies were identified by PLWDs and care partners (CPs) through semi‐structured interviews, who were involved in the convening process, aimed at exploring ways to enhance facilitation techniques for participants. Conclusion Additionally, these summarized insights aim to encourage the use of community‐engaged approaches in discussions and consensus‐building around research priorities in emergency care, particularly for PLWDs and their CPs.
LTBK-02. EVALUATION OF PAXALISIB IN GBM AGILE PHASE 3 REGISTRATION PLATFORM TRIAL FOR NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA
Mellinghoff, Ingo K. , Berry, Donald A. , Buxton, Meredith , Colman, Howard , Gordon, Gary, Lassman, Andrew B. , Lim, Michael , Perry, James , Wen, Patrick Y. , Yung, W.K. Alfred , Berry, Nicholas , Graves, Todd, Detry, Michelle A. , Hyddmark, Emma Maria Viktoria, Johnsson, Adam, Kling, Heather M., Powell, Ashley A., Untch, Sarah, Aquilanti, Elisa , Blondin, Nicholas, Boulmay, Brian C., Fuente, Macarena de la, Lobbous, Mina , Mikkelsen, Tom , Newton, Herbert B. , Schiff, David , Sherman, Wendy, Weathers, Shiao-Pei, Friend, John, Lee, E., Mellinghoff, Ingo K , Cloughesy, Timothy F. , Alexander, Brian M. , Cavenee, Webster K. , Colman, Howard , Groot, John de , Ellingson, Benjamin M. , Khasraw, Mustafa , Sulman, Erik P. , Weller, Michael , Wen, Patrick Yung , Johnsson, Adam, McGlothlin, Anna , Powell, Ashley, Drappatz, Jan , Jordan, Justin T. , Kaley, Thomas , Owen, Scott , Peters, Katherine B. , Schiff, David, Weathers, Shiao‐Pei , Youssef, Michael , Friend, John

Mayo Clinic

Neuro-Oncology | November 22, 2024 | Volume: 26 | Issue: Supplement_8 | Pages: viii1-viii1

10.1093/neuonc/noae165.1302 Get It

Abstract GBM AGILE(NCT03970447) is a phase 2/3 Bayesian adaptive registration platform trial testing multiple therapies against a common control. Paxalisib, a PI3K/mTOR inhibitor, is the 3rd arm in the trial to conclude evaluation. METHODS Paxalisib was open to patients with newly diagnosed unmethylated (NDU) and recurrent (RD) glioblastoma, with three possible signatures: NDU, RD, and All(NDU+RD). Arm enrollment occurred Dec2020 through May2022. Control patients were enrolled from study initiation (July2019) and were treated with temozolomide(NDU) or lomustine(RD). GBM AGILE investigational arms have 1 or 2 stages, with adaptive randomization in stage 1 and fixed randomization if arms continue to stage 2. Efficacy is based on OS hazard ratio(HR) of Arm/Control. Efficacy goal is final Bayesian probability ≥ 98% for HR&lt;1.00 in combined Stages. An Arm continues to Stage 2 if Bayesian predictive power (PP) ≥ 0.8. An Arm stops accruing in Stage 1 if it reaches maximal sample size(N) or does not meet a minimum efficacy threshold (PP&lt;0.25 for all signatures when N&gt;50). Clinical cut-off is 12 months after accrual stops. The maximum N for paxalisib was approximately 150(Stage 1) and 50(Stage 2). RESULTS After paxalisib reached &gt;150 patients in Stage 1, accrual stopped [Paxalisib/control N 54/75(NDU), 100/188(RD)]. Neither PP thresholds for moving to Stage 2 nor stopping for minimum efficacy were met. Following an unplanned public disclosure that the arm did not continue to stage 2, clinical cut-off for final analysis (planned May2023) was updated to public disclosure date (August2022). At final analysis mean HRs were 0.89(NDU), 1.25(RD), 1.05(All), probabilities of HR&lt;1.00 of 0.72(NDU), 0.076(RD), 0.398(All). Model estimated median OS paxalisib/control (months) were 14.77/13.84(NDU) and 8.58/10.06(RD). CONCLUSION Paxalisib did not show survival benefit over cumulative control in final primary analysis; additional secondary analyses are being considered. GBM AGILE continues to rapidly and efficiently assess therapies in ND and RD glioblastoma.